Cargando…

Effects on LOS may not justify cost of remdesivir for severe COVID-19

Detalles Bibliográficos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2021
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7790512/ https://www.ncbi.nlm.nih.gov/pubmed/33437147 http://dx.doi.org/10.1007/s40274-021-7380-1

Ejemplares similares

Remdesivir cost effective for severe COVID-19 in China
Publicado: (2021)

Remdesivir may be cost saving in eligible patients during COVID-19 infections in Germany
Publicado: (2021)

Baricitinib + remdesivir cost saving vs remdesivir for hospitalised COVID-19 patients in the USA
Publicado: (2021)

Remdesivir appears to save costs in COVID-19 patients on low-flow oxygen therapy in Turkey
Publicado: (2021)

Benefit-risk assessment for remdesivir in COVID-19
Publicado: (2020)

Remdesivir vs tocilizumab in COVID-19: adverse event profiles
Publicado: (2021)

Quality of ADR reporting evaluated for remdesivir trials of COVID-19
Publicado: (2020)

Remdesivir use in severe renal impairment: benefits outweigh risks
Publicado: (2021)

Remdesivir does not increase risk of AKI or ALI in COVID-19 patients
Publicado: (2022)

COVID-19-related decreases in paediatric PCV 13 use does not justify vaccination of older adults
Publicado: (2021)

The Cost-Effectiveness of Remdesivir for Hospitalized Patients With COVID-19
por: Whittington, Melanie D., et al.
Publicado: (2022)

Testing and restrictions are cost-effective COVID-19 measures
Publicado: (2021)

COVID-19 vaccination predicted to be cost effective in USA
Publicado: (2021)

Cost-effectiveness of Remdesivir and Dexamethasone for COVID-19 Treatment in South Africa
por: Jo, Youngji, et al.
Publicado: (2021)

Cost-Effectiveness of Remdesivir for COVID-19 Treatment: What Are We Missing?
por: Chhatwal, Jagpreet, et al.
Publicado: (2022)

Cost effective COVID-19 mitigation measures in US colleges
Publicado: (2021)

Productivity losses impact cost effectiveness of COVID-19 vaccine
Publicado: (2021)

Tocilizumab cost effective in reducing COVID-19-related deaths
Publicado: (2021)

Expanded testing for COVID-19 could be cost effective in USA
Publicado: (2020)

COVID-19 control strategies cost effective in South Africa
Publicado: (2020)

Comparing the efficacy of regen-cov, remdesivir, and favipiravir in reducing invasive mechanical ventilation need in hospitalized COVID-19 patients
por: Hegazy, Sahar Kmal, et al.
Publicado: (2023)

Potential Effects of Remdesivir on Tacrolimus Exposure in Transplant Recipients With COVID-19 Infection
por: Habeeb, Ehsan, et al.
Publicado: (2023)

Down syndrome: the aggravation of COVID-19 may be partially justified by the expression of TMPRSS2
por: Evangelho, Victor Gustavo Oliveira, et al.
Publicado: (2021)

Use and Safety of Remdesivir in Kidney Transplant Recipients With COVID-19
por: Buxeda, Anna, et al.
Publicado: (2021)

ICU bed reserve capacity for COVID-19 cost effective in Germany
Publicado: (2021)

REMDESIVIR-INDUCED EXTREME SINUS BRADYCARDIA IN COVID-19
por: Hamilton, Steven A., et al.
Publicado: (2022)

COVID-19: stigmatising the unvaccinated is not justified
por: Kampf, Günter
Publicado: (2021)

COVID-19 vaccination may reactivate varicella-zoster virus
Publicado: (2022)

Costs of active COVID-19 testing in Canada
Publicado: (2020)

Cost-benefit of COVID-19 lockdown in the UK
Publicado: (2020)

The effect of the severity of COVID-19 on the sequelae of the audiovestibular system
por: Aydin, Sukru, et al.
Publicado: (2022)

Length of remdesivir treatment in patients with severe COVID-19
por: Ippolito, Mariachiara, et al.
Publicado: (2021)

Compassionate Use of Remdesivir for Patients with Severe Covid-19
por: Grein, Jonathan, et al.
Publicado: (2020)

Is It Time to Revisit Remdesivir Use for Severe COVID-19?
por: Taggarsi, Dipali Anand
Publicado: (2022)

Remdesivir treatment for patients with moderate to severe COVID-19
por: HASANOĞLU, İmran, et al.
Publicado: (2022)

Efficacy of remdesivir for hospitalized COVID-19 patients with end stage renal disease
por: Selvaraj, Vijairam, et al.
Publicado: (2022)

Cost-justifying usability: an update for the internet age
por: Bias, Randolph G, et al.
Publicado: (2005)

Remdesivir-related cost-effectiveness and cost and resource use evidence in COVID-19: a systematic review
por: Murton, Molly, et al.
Publicado: (2022)

Baricitinib + SOC cost effective vs SOC for patients hospitalised with COVID-19 in the USA
Publicado: (2021)

Remdesivir and COVID-19
por: Ferrara, Francesco, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_ei3fu5f3k39klmn4gn15amco4u